Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in IPF therapeutics.

• There will be more than 0.49 million diagnosed prevalent cases of IPF in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for IPF.
• Currently, there are two leading marketed drugs for the treatment of IPF, with Roche and Boehringer Ingelheim being key players in the disease space.
• R&D activity in IPF is steady, with one product in pre-registration stage and three products in Phase III development.
• Commercial sponsors dominate clinical trial development in IPF, with the US emerging as the key country for conducting trials in this disease space.
• Globally, deals involving partnerships were the most common type of deals involving companies developing
• There will be more than 0.49 million diagnosed prevalent cases of IPF in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for IPF.
• Currently, there are two leading marketed drugs for the treatment of IPF, with Roche and Boehringer Ingelheim being key players in the disease space.
• R&D activity in IPF is steady, with one product in pre-registration stage and three products in Phase III development.
• Commercial sponsors dominate clinical trial development in IPF, with the US emerging as the key country for conducting trials in this disease space.
• Globally, deals involving partnerships were the most common type of deals involving companies developing IPF assets.

Scope

GlobalData’s IPF: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include-

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the IPF market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.